Oct 01, 2018
Theravance Biopharma to Present New Data from Multiple Studies of VIBATIV® (telavancin) at IDWeek(TM) 2018
Sep 25, 2018
Theravance Biopharma to Present at the 2018 Cantor Global Healthcare Conference
Sep 24, 2018
Theravance Biopharma Highlights Positive CHMP Opinion Supporting Expanded COPD Indication for Trelegy Ellipta in Europe
Sep 17, 2018
Theravance Biopharma and Mylan Report New Data from Phase 3 Studies of YUPELRI(TM) (revefenacin) in Oral Presentation at the European Respiratory Society International Congress
Aug 01, 2018
Theravance Biopharma, Inc. Reports Second Quarter 2018 Financial Results and Provides Business Update
Aug 01, 2018
Theravance Biopharma Reports Positive Top-Line Four-Week Data from Phase 2 Trial of TD-9855 for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension
Jul 25, 2018
Theravance Biopharma to Report Second Quarter 2018 Financial Results on August 1
May 17, 2018
Theravance Biopharma to Host Key Opinion Leader Event Focused on the Unmet Medical Need in the Treatment of Neurogenic Orthostatic Hypotension
May 10, 2018
Theravance Biopharma to Present at the Bank of America Merrill Lynch 2018 Healthcare Conference
May 08, 2018
Theravance Biopharma, Inc. Reports First Quarter 2018 Financial Results and Provides Business Update
May 01, 2018
Theravance Biopharma to Report First Quarter 2018 Financial Results on May 8, 2018
Apr 25, 2018
Theravance Biopharma Highlights Approval of Expanded Indication in the US for Once-Daily Trelegy Ellipta for Treatment of COPD Patients
Apr 23, 2018
Theravance Biopharma Reports Positive New Data from Multiple Studies of VIBATIV® (telavancin) at 2018 ECCMID(TM) Conference
Apr 19, 2018
Theravance Biopharma Highlights Landmark IMPACT Study Published in NEJM Showing Significant Benefits of Trelegy Ellipta for COPD Patients
Apr 17, 2018
Theravance Biopharma to Present New Data from Multiple Studies of VIBATIV® (telavancin) at 2018 ECCMID(TM) Conference
Mar 21, 2018
Theravance Biopharma to Present at the 17th Annual Needham Healthcare Conference
Feb 27, 2018
Theravance Biopharma, Inc. Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Update
Feb 20, 2018
Theravance Biopharma to Report Fourth Quarter and Full Year 2017 Financial Results on February 27, 2018
Feb 07, 2018
Theravance Biopharma Enters Global Collaboration with Janssen for TD-1473 in Inflammatory Intestinal Diseases
Jan 29, 2018
Theravance Biopharma and Mylan Announce FDA Acceptance of New Drug Application for Revefenacin (TD-4208) in Adults with Chronic Obstructive Pulmonary Disease